WALDW — Waldencast plc

Summary of Waldencast Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $65.4 million, a decline of 4.1% year-over-year.
• Adjusted Gross Profit Margin: 76.4%, up 10 basis points from the previous year.
• Adjusted EBITDA: $4.4 million, representing a margin of 6.7%.
• Milk Makeup Revenue: Declined 15.1%, with a strong domestic performance offset by international challenges.
• Obagi Medical Revenue: Increased 7.1% to $36.2 million, despite out-of-stock issues.
• Cash Position: $10.8 million, with an additional $22.5 million available from a revolving credit facility.
• Net Debt: Increased to $172.1 million from $154.2 million.

2. Strategic Updates and Business Highlights

• Brand Growth Initiatives: Focus on innovation and expansion for Milk Makeup and Obagi Medical, with successful product launches like Hydro Grip Gel Skin Tint.
• Distribution Expansion: Milk Makeup launched in Ulta Beauty, contributing to high single-digit growth in U.S. retail sales.
• Supply Chain Improvements: Ongoing restructuring to enhance operational efficiency and product availability.
• Digital Growth: Both brands saw continued growth in digital channels, with Obagi benefiting from a successful consumer acquisition strategy.

3. Forward Guidance and Outlook

• Revenue Growth Target: Mid-teens growth for fiscal 2025.
• Adjusted EBITDA Margin: Expected in the mid to high-teens.
• Key Growth Drivers: Continued innovation, expansion in retail and digital channels, and improved fulfillment rates.

4. Challenges and Points of Concern

• Declining Revenue: Overall revenue decline due to tough comparisons from last year and a decelerating beauty market.
• Supply Chain Disruptions: Out-of-stock issues for key products at Obagi, affecting growth.
• International Performance: Milk Makeup faced challenges in international markets due to tough comparisons and inventory adjustments.
• Macroeconomic Pressures: Anticipated pressure from softer consumer sentiment and potential tariff impacts on cost of goods.

5. Notable Q&A Insights

• Supply Chain Restructuring: Management emphasized the need for improved supply chain flexibility and responsiveness to meet demand.
• Physician Channel Performance: No significant slowdown in the physician channel, but growth was tempered compared to last year due to changes in the Amazon business model.
• Pricing Strategy: Management is monitoring tariff impacts and believes they can manage costs with selective price increases if necessary.
• Ulta Beauty Launch: Early results from Ulta indicate strong performance and potential for further expansion within the retailer's network.

Overall, Waldencast is navigating a challenging environment but remains optimistic about its growth potential, driven by strategic initiatives and brand strength.